Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
| العنوان: | Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population |
|---|---|
| المؤلفون: | Ronan Mahon, Dorothy L. Keininger, Job F M van Boven, Nicolas Roche, Leif Bjermer, Florian S. Gutzwiller, Madlaina Costa-Scharplatz, Karin Lisspers, Petter Olsson |
| المساهمون: | Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Value, Affordability and Sustainability (VALUE), Groningen Research Institute for Asthma and COPD (GRIAC) |
| المصدر: | Respiratory Research Respiratory Research, 18:206. BioMed Central Ltd. Respiratory Research, Vol 18, Iss 1, Pp 1-10 (2017) |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Male, Exacerbation, Salmeterol fluticasone, Respiratory Medicine and Allergy, Cost-Benefit Analysis, INHALED CORTICOSTEROIDS, Quinolones, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Medicine, 030212 general & internal medicine, health care economics and organizations, Lungmedicin och allergi, Fluticasone, RISK, COPD, Chronic obstructive pulmonary disease, Middle Aged, Fluticasone-Salmeterol Drug Combination, Drug Combinations, Models, Economic, Population Surveillance, Indans, Female, Salmeterol, medicine.drug, Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi, medicine.medical_specialty, animal structures, Pulmonary disease, OBSTRUCTIVE PULMONARY-DISEASE, SALMETEROL-FLUTICASONE, 03 medical and health sciences, Swedish population, Double-Blind Method, Internal medicine, Humans, COMBINATION, Indacaterol/glycopyrronium, Aged, lcsh:RC705-779, Sweden, business.industry, Research, QVA149, Health Care Service and Management, Health Policy and Services and Health Economy, lcsh:Diseases of the respiratory system, Cost-effective, medicine.disease, Glycopyrrolate, SEVERITY, 030228 respiratory system, Indacaterol, business |
| الوصف: | Background This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. Methods A previously published and validated patient-level simulation model was adapted using clinical data from the FLAME trial and real-world cost data from the ARCTIC study. Costs (total monetary costs comprising drug, maintenance, exacerbation, and pneumonia costs) and health outcomes (life-years (LYs), quality-adjusted life-years (QALYs)) were projected over various time horizons (1, 5, 10 years, and lifetime) from the Swedish payer’s perspective and were discounted at 3% annually. Uncertainty in model input values was studied through one-way and probabilistic sensitivity analyses. Subgroup analyses were also performed. Results IND/GLY was associated with lower costs and better outcomes compared with SFC over all the analysed time horizons. Use of IND/GLY resulted in additional 0.192 LYs and 0.134 QALYs with cost savings of €1211 compared with SFC over lifetime. The net monetary benefit (NMB) was estimated to be €8560 based on a willingness-to-pay threshold of €55,000/QALY. The NMB was higher in the following subgroups: severe (GOLD 3), high risk and more symptoms (GOLD D), females, and current smokers. Conclusion IND/GLY is a cost-effective treatment compared with SFC in COPD patients with mMRC dyspnea grade ≥ 2, moderate to very severe airflow limitation, and ≥1 exacerbation in the preceding year. Electronic supplementary material The online version of this article (10.1186/s12931-017-0688-5) contains supplementary material, which is available to authorized users. |
| وصف الملف: | application/pdf |
| تدمد: | 1465-993X 1465-9921 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2990a6505beb73864bba0a826bd42fdcTest https://pubmed.ncbi.nlm.nih.gov/29228950Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2990a6505beb73864bba0a826bd42fdc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1465993X 14659921 |
|---|